KEY DETAILS
Starting July 1, 2026, a Medicare program called the GLP-1 Bridge will cover some GLP-1 drugs for weight loss for a $50 monthly copay, for people who meet its weight and health criteria.
In April, CMS put off the Medicare Part D part of its longer-term BALANCE GLP-1 model with no new date, and extended the short-term GLP-1 Bridge through the end of 2027.
Fractyl Health received approval in the Netherlands to start the first human trial of a GLP-1 gene therapy, RJVA-001, in people with type 2 diabetes and obesity.
A study of 600,000 people suggests GLP-1 drugs may help fight addiction broadly.
The FDA approved Lilly's Foundayo (orforglipron), a daily GLP-1 pill for weight loss, on April 1, 2026, and it has been available by prescription since early April.
Starting July 1, 2026, a Medicare program called the GLP-1 Bridge will cover some GLP-1 drugs prescribed for weight loss, a shift that could affect coverage for many older adults. Separately, in April, CMS put off the Part D part of its longer-term BALANCE model, with no new date. If you rely on Medicare and have been waiting on this drug class, the details below are worth a close look.
Under the GLP-1 Bridge, Medicare will pay for Wegovy, Foundayo or Zepbound when the prescription is written for weight loss, for a $50 monthly copay. This is a change from long-standing Medicare policy, which historically excluded weight-loss-only prescriptions from coverage. The Bridge runs separately from regular Part D plans, requires prior authorization, and is limited to people who meet its weight and health criteria. I would suggest asking your prescriber whether you qualify before the July 1 start.
The delay applies to a different, longer-term program. In April, CMS put off the Medicare Part D part of its BALANCE model, which had been planned for 2027, and did not set a new date. In the same announcement it extended the short-term GLP-1 Bridge through December 31, 2027. The Bridge's July 1 start is not affected by that delay. If you were planning around the larger program, the Bridge is the option with a firm date.
Separately, Fractyl Health received approval in the Netherlands to begin the first human trial of a GLP-1 gene therapy, RJVA-001, in people with type 2 diabetes and obesity, a treatment approach designed to work differently from the injectable or oral drugs currently on the market. Gene therapy aims to prompt the body to produce its own GLP-1 effect over a longer period, rather than relying on repeated dosing. This is an early-stage trial, so the therapy has not been proven safe or effective in people yet, and any potential availability is likely years away. Patients currently on GLP-1 medications should not expect this development to affect their treatment in the near term.
A study following 600,000 people found associations between GLP-1 drug use and lower rates of several substance use disorders, suggesting the drugs may have effects that extend beyond weight and blood sugar. The substances involved reportedly spanned multiple categories, which is why the study's authors describe the pattern as broad rather than limited to one type of addiction. This kind of large observational study can show a correlation without proving that GLP-1 drugs directly caused the reduction in substance use. Researchers will need controlled trials to confirm whether these medications actually change addiction risk or whether other factors explain the pattern.
Orforglipron, an oral GLP-1 medication sold as Foundayo, was approved by the FDA for weight loss on April 1, 2026, and has been available by prescription since early April. It is one of the few pill-form options in a category dominated by injectables. An oral option could appeal to patients who prefer not to inject themselves. Coverage and pricing vary, so patients interested in switching should ask their prescriber and insurer about cost before making changes.
Given how much is still shifting with Medicare's GLP-1 Bridge, the delay to the longer-term plan and these newer treatment developments, the most useful step you can take right now is to confirm your own coverage and treatment status directly with your Medicare plan or prescriber rather than relying on early reports. If you are considering a change based on gene therapy trials or a new oral option, ask specifically about availability and cost in your area before adjusting your current treatment. Staying in touch with your care team will keep you better positioned to act as these programs get underway.